Perioperative ivonescimab in resectable NSCLC: combination MPR 70.1% (operated) / 59.5% (FAS)
Neoadjuvant ivonescimab alone or with chemotherapy was followed by surgery and adjuvant ivonescimab in patients with resectable NSCLC. Among operated patients, major pathological response (MPR) was observed in 6/10 receiving monotherapy (60.0%) and 47/67 receiving combination treatment (70.1%); by full analysis set (FAS, all enrolled), combination MPR was 59.5%. The combination cohort met its prespecified historical-control-based primary endpoint (80% CI lower bound exceeded 41% historical control).

Background and open questions
Perioperative immunotherapy has improved outcomes in resectable non-small cell lung cancer (NSCLC), but the optimal regimen is still evolving. Ivonescimab is a bispecific antibody targeting both PD-1 and VEGF, combining checkpoint inhibition with anti-angiogenic activity in a single molecule. Whether this dual mechanism could improve pathological responses in the neoadjuvant setting remained untested.
Study design
This nonrandomized, noncomparative phase 2 trial enrolled 90 patients with resectable NSCLC. Patients received neoadjuvant ivonescimab alone (11 patients) or with platinum-based chemotherapy (79 patients), followed by surgery and adjuvant ivonescimab. The primary endpoint was major pathological response (MPR), with the combination cohort designed to test against a historical control.
Key results
- In the monotherapy cohort, 6 of 10 operated patients achieved MPR (60.0%).
- In the combination cohort, 47 of 67 operated patients achieved MPR (70.1%), meeting the prespecified primary endpoint.
- Grade ≥3 treatment-related adverse events occurred in 4 of 11 monotherapy patients and 24 of 79 combination patients.
- No grade ≥3 hemorrhage or treatment-related deaths occurred.
Mechanistic interpretation
The dual PD-1 and VEGF blockade may enhance antitumor immunity by both relieving T-cell suppression and normalizing the tumor vasculature, potentially improving immune cell infiltration. The pathological response rates suggest this approach warrants further investigation in randomized trials.
Limitations
- The study design is nonrandomized and noncomparative; it does not demonstrate superiority over current perioperative standards.
- Sample sizes are small, particularly in the monotherapy cohort (10 evaluable for surgical response).
- Long-term survival outcomes are not yet available.
Authors and source
Nature Medicine (2026). Published online 4 November 2026. https://doi.org/10.1038/s41591-026-04745-4.
Numbers are as reported by the authors. Corrections: contact@
Related science
MDT-BRIDGE: neoadjuvant durvalumab plus chemotherapy, then surgery or chemoradiotherapy by team decision
MDT-BRIDGE: neoadjuvant durvalumab plus chemotherapy, then MDT-guided surgery or chemoradiotherapy.
PHERGain 5-year data: PET-guided chemotherapy de-escalation in HER2-positive early breast cancer
PHERGain: PET-guided de-escalation with trastuzumab and pertuzumab.
First-in-class METTL1 inhibitor STM9005 cuts tRNA m7G and slows AML and solid-tumor models
STM9005 blocks METTL1–WDR4, lowering tRNA m7G and translation of oncogenic mRNAs.
One email, with links to every paper. Reports and custom landscapes: contact@inlightbio.com.
Opens your email app with a pre-filled request; we add you by hand. Free, unsubscribe any time.


